SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?


To: DewDiligence_on_SI who wrote (2435)6/30/2005 6:27:50 PM
From: Miljenko Zuanic  Respond to of 3044
 
<<1. PTK has not failed yet, although it did miss an interim endpoint in progression-free survival in one of two pivotal trials.>>

IF it did not worked well in first line why should work in second line?

<<2. I would not characterize NVS’ oncology pipeline as weak.>>

Except new Glevec (competing drug emerging) and (maybe) m-TOR (again few competing candidates) what do you see as exciting?

Miljenko